Angeles Wealth Management LLC Has $579,000 Holdings in Zoetis Inc. $ZTS

Key Points

• Angeles Wealth Management LLC increased its stake in Zoetis Inc. by 125.7%, now holding shares worth $579,000 after acquiring additional shares in the second quarter.
• Zoetis reported a Q2 EPS of $1.76, exceeding analyst expectations, and achieved a year-over-year revenue growth of 4.2% to $2.46 billion.
• The company has announced a quarterly dividend of $0.50, with a dividend yield of 1.4%, payable on December 2nd.

Angeles Wealth Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 125.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,713 shares of the company's stock after acquiring an additional 2,068 shares during the quarter. Angeles Wealth Management LLC's holdings in Zoetis were worth $579,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. Nova Wealth Management Inc. acquired a new position in Zoetis during the 1st quarter worth $25,000. 1248 Management LLC acquired a new position in Zoetis during the 1st quarter worth $27,000. Saudi Central Bank acquired a new position in Zoetis during the 1st quarter worth $29,000. Cornerstone Planning Group LLC lifted its holdings in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC lifted its holdings in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock worth $31,000 after buying an additional 131 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Price Performance

ZTS opened at $144.15 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $193.49. The company has a fifty day simple moving average of $148.73 and a 200 day simple moving average of $153.76. The stock has a market cap of $63.88 billion, a P/E ratio of 24.81, a P/E/G ratio of 2.30 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter in the prior year, the company earned $1.56 EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis's dividend payout ratio is currently 34.42%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Argus reaffirmed a "buy" rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a report on Wednesday, October 8th. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.